Citizens reiterates Immix Biopharma stock rating on pipeline progress

Citizens, a firm specializing in stock ratings, has maintained an 'Outperform' rating on Immix Biopharma, Inc. (NASDAQ:IMMX) along with an upwardly revised price target of $23.00. This assessment is based on an analysis of the company's revenue and earnings multiples. Immix recently disclosed its second-quarter 2026 earnings, which have sparked optimism among analysts.

Imix Biopharma currently trades at $10.92, significantly below the firm's target price, although the stock has experienced an impressive 399% return over the last year. The company has indicated that its investigational new drug candidate, NXC-201, is on track to report positive top-line results in September and file a Biologics License Application (BLA) in the first half of 2027. A potential commercial launch for this product is anticipated by the end of 2026 or early 2027.

Imix holds a substantial cash reserve of $232.1 million, reflecting a robust financial position. The company boasts an exceptional balance sheet, characterized by zero debt and a current ratio of 25.13, which underscores its financial stability. However, InvestingPro data suggests that the stock may be overvalued at its current valuation when compared to its intrinsic Fair Value.

The rating agency notes that Immix Biopharma shares present an appealing investment opportunity, with the potential for a modest downside of around 47% if market conditions deteriorate, bringing the stock price down to $6. Conversely, the company's shares could see substantial gains of approximately 273% if favorable market conditions prevail, potentially propelling the stock price to $42.

In a related development, Immix Biopharma reported a net loss of $0.18 per share for the second quarter of 2026, which exceeded the anticipated loss of $0.15 per share. The company's research and development expenses were recorded at $5.3 million, while selling, general, and administrative expenses rose to $7.1 million, surpassing earlier projections.

In a strategic move, Immix Biopharma successfully executed a significant stock offering, raising approximately $140.65 million from U.S. biotechnology institutional investors and mutual funds. This capital infusion further strengthens the company's financial position.

Moreover, investment firm H.C. Wainwright has raised its price target for Immix Biopharma to $25, retaining its 'Buy' rating, thereby expressing confidence in the company's future prospects. Additionally, BofA Securities has initiated coverage of Immix Biopharma with a 'Buy' rating and a more ambitious price target of $27, citing promising early data regarding the efficacy of their AL amyloidosis drug, NXC-201.

However, the story takes an unexpected turn with the revelation that Ronald Fischer, an executive at Immix Biopharma, was a fugitive who was apprehended last week. This development adds a layer of complexity to the company's operations.

H.C. Wainwright's prior price target increase to $20, following positive trial data from the Phase 2 NEXICART-2 trial, where four patients achieved a complete response, further emphasizes the positive trajectory of Immix Biopharma's research efforts. These multifaceted developments offer a comprehensive view of the company's financial, operational, and legal landscape, highlighting both challenges and opportunities for Immix Biopharma.